These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3980330)

  • 61. [Simplified liquid nutrient media for controlling antibiotic activity, the spectrum of their antibacterial action and the sensitivity of microorganisms].
    Semenov SM; Tikhonov AS
    Antibiotiki; 1977 Mar; 22(3):216-9. PubMed ID: 15506
    [TBL] [Abstract][Full Text] [Related]  

  • 62. What is inadequate antibacterial therapy?
    Moellering RC
    Clin Infect Dis; 2009 Oct; 49(7):1006-8. PubMed ID: 19719418
    [No Abstract]   [Full Text] [Related]  

  • 63. In vitro antibacterial activities of two novel oral antibiotics, tebipenem and cefditoren, and other comparators against community-acquired respiratory tract infection-associated bacterial pathogens: a multicentre study in China.
    Li H; Wang Z; Zhang F; Wang Q; Chen H; Zhao C; Wang H
    Int J Antimicrob Agents; 2014 Jan; 43(1):92-3. PubMed ID: 24183753
    [No Abstract]   [Full Text] [Related]  

  • 64. Setting and revising antibacterial susceptibility breakpoints.
    Turnidge J; Paterson DL
    Clin Microbiol Rev; 2007 Jul; 20(3):391-408, table of contents. PubMed ID: 17630331
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [New data, established in vitro and in vivo, on the sensitivity of anaerobic bacteria to antibiotics].
    Bittner J; Antohi M; Ardeleanu J; Munteanu V; Lemeni D; Macovei A
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1987; 32(1):11-22. PubMed ID: 3589387
    [No Abstract]   [Full Text] [Related]  

  • 66. In vitro and ex vivo systems at the forefront of infection modeling and drug discovery.
    Shi D; Mi G; Wang M; Webster TJ
    Biomaterials; 2019 Apr; 198():228-249. PubMed ID: 30384974
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [A micromethod for studying the sensitivity of anaerobic bacteria to antibiotics].
    Nadaud M
    Ann Biol Clin (Paris); 1983; 41(2):113-22. PubMed ID: 6881623
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
    Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2015 Feb; 45(2):161-7. PubMed ID: 25481459
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Value of laboratory methods for elaboration of rational tactics in antibiotic therapy].
    Navashin SM; Fomina IP; Pozdniakova VP
    Lab Delo; 1984; (5):295-9. PubMed ID: 6204115
    [No Abstract]   [Full Text] [Related]  

  • 71. Dual individualization: antibiotic dosage calculation from the integration of in-vitro pharmacodynamics and in-vivo pharmacokinetics.
    Schentag JJ; Swanson DJ; Smith IL
    J Antimicrob Chemother; 1985 Jan; 15 Suppl A():47-57. PubMed ID: 3980336
    [No Abstract]   [Full Text] [Related]  

  • 72. New synthetic antibacterial compound, 1-(2-hydroxyethyl)-3-nitro-4-pyrazole carboxamide.
    Wick WE; Preston DA; Terando NH; Welles JS; Gordee RS
    Antimicrob Agents Chemother; 1973 Sep; 4(3):343-5. PubMed ID: 4758837
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Proximate and ultimate causes of the bactericidal action of antibiotics.
    Baquero F; Levin BR
    Nat Rev Microbiol; 2021 Feb; 19(2):123-132. PubMed ID: 33024310
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In vitro models for the study of antibiotic activities.
    Blaser J; Zinner SH
    Prog Drug Res; 1987; 31():349-81. PubMed ID: 3326034
    [No Abstract]   [Full Text] [Related]  

  • 75. Animal models as predictors of the safety and efficacy of antibiotics.
    Zak O; O'Reilly T
    Eur J Clin Microbiol Infect Dis; 1990 Jul; 9(7):472-8. PubMed ID: 2226475
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of MSD-819 (6-chloro-2-quinoxalinecarboxylic acid 1,4-dioxide).
    Ooi N; O'Neill AJ
    J Antibiot (Tokyo); 2017 Mar; 70(3):317-319. PubMed ID: 27899790
    [No Abstract]   [Full Text] [Related]  

  • 77. Rifampin.
    Farr B; Mandell GL
    Med Clin North Am; 1982 Jan; 66(1):157-68. PubMed ID: 7038325
    [No Abstract]   [Full Text] [Related]  

  • 78. Bacterial resistance to antibiotics. A correlation of clinically attainable blood levels with in vitro sensitivity tests.
    PULLEN FW
    Arch Surg; 1960 Dec; 81():942-52. PubMed ID: 13738458
    [No Abstract]   [Full Text] [Related]  

  • 79. Resistance as a cause of treatment failure.
    Phillips I
    J Antimicrob Chemother; 1986 Oct; 18 Suppl C():255-60. PubMed ID: 3804897
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Use of rifampin in nonstaphylococcal, nonmycobacterial disease.
    Morris AB; Brown RB; Sands M
    Antimicrob Agents Chemother; 1993 Jan; 37(1):1-7. PubMed ID: 8431003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.